News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Cardiome Pharma Corp. Says Heart Drug Program Delayed, Shares Fall
August 11, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Aug 11 (Reuters) - Canada's Cardiome Pharma Corp (COM.TO) said the development of its key drug to treat irregular heart beats will be delayed, sending its shares down as much as 18 percent on Wednesday morning.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
FDA
Approvals
MORE ON THIS TOPIC
Obesity
Structure Stock Soars as Oral GLP-1 Generates ‘Highly Competitive’ Weight Loss
December 9, 2025
·
2 min read
·
Tristan Manalac
Infectious disease
Assembly’s Antivirals Show ‘Striking’ Drop in Lesions, Viral Shedding in Early Genital Herpes Study
December 9, 2025
·
2 min read
·
Tristan Manalac
Policy
As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation
December 8, 2025
·
3 min read
·
Jennifer Smith-Parker
Weight loss
Wave Soars on Early Results for Obesity Treatment That Could ‘Disrupt’ the Landscape
December 8, 2025
·
1 min read
·
Dan Samorodnitsky
